Table 1 |
||
|
Odds ratios for having the metabolic syndrome in patients receiving methotrexate monotherapy compared with those not on methotrexate |
||
| NCEP 2004 |
NCEP 2001 |
|
| OR (95% CI) |
OR (95% CI) |
|
| n = 62 |
n = 62 |
|
|
|
||
| Crude |
0.415 (0.21-0.82), |
0.368 (0.19-0.73), |
| P = 0.011 |
P = 0.004 |
|
| Model a |
0.421 (0.21-0.84), |
0.373 (0.19-0.75), |
| P = 0.014 |
P = 0.006 |
|
| Model b |
0.468 (0.23-0.99), |
0.408 (0.19-0.84), |
| P = 0.038 |
P = 0.015 |
|
|
|
||
|
Crude: Unadjusted model. Model a: adjusted for age and gender. Model b: adjusted for age, gender, disease duration, erythrocyte sedimentation rate, and health assessment questionnaire score. CI, confidence interval; NCEP, National Cholesterol Education Program; OR, odds ratio. |
||
|
Toms et al. Arthritis Research & Therapy 2009 11:414 doi:10.1186/ar2806 |
||